Related Experiment Videos

[Clinical experience with cefotiam (author's transl)]

Insights

Cefotiam (CTM) demonstrated good to fair clinical efficacy in treating pediatric infections like acute tonsillitis and bronchopneumonia. Bacterial eradication was achieved in most cases with minimal side effects.

Area of Science:

  • Pediatric Infectious Diseases
  • Clinical Pharmacology
  • Bacteriology

Background:

  • Cefotiam (CTM) is a cephalosporin antibiotic.
  • Assessing CTM's clinical utility in pediatric patients is important for treatment guidelines.

Observation:

  • Six pediatric patients (five 1-year-olds, one 7-year-old) with acute tonsillitis, phlegmon, bronchopneumonia, and cervical abscess were treated with CTM.
  • CTM was administered intravenously at 50-115 mg/kg/day in divided doses for 4-8 days.
  • Causative pathogens included Staphylococcus aureus, Haemophilus parainfluenzae, and Klebsiella pneumoniae.

Findings:

  • Bacterial eradication was successful in 5 out of 6 cases, with S. aureus being the only persistent pathogen in one instance.
  • Overall clinical response was good in 4 patients and fair in 2 patients.
  • Transient elevations in liver enzymes (GOT, GPT) were noted in one patient; no other adverse effects were reported.

Implications:

  • Cefotiam exhibits promising clinical effectiveness and a favorable safety profile for treating various pediatric bacterial infections.
  • Further investigation into CTM's efficacy against resistant strains like S. aureus may be warranted.

Related Concept Videos